A MULTICENTER ASSESSMENT OF SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) WHO RECEIVED IMMUNE CHECKPOINT INHIBITOR THERAPY (ICI) WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY (CN)

被引：0
|
作者：
Gross, Evan
Li, Mingjia
Yin, Ming
Orcutt, Delaney
Hussey, Duncan
Trott, Elliot
Kramer, Joel
Oliva, Kaylee
Gore, John
Schade, George
Lin, Daniel
Tykodi, Scott
Hall, Evan
Thompson, John
Parikh, Anish
Yang, Yuanquan
Collier, Katharine
Miah, Abdul
Mori-Vogt, Sherry
Hinkley, Megan
Mortazavi, Amir
Monk, Paul
Folefac, Edmund
Clinton, Steven
Psutka, Sarah
机构：
来源：
JOURNAL OF UROLOGY | 2021年 / 206卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
MP14-08
引用
收藏
页码：E255 / E255
页数：1
相关论文
共 50 条
  • [1] Impact of cytoreductive nephrectomy (CN) on survival in metastatic renal cell cancer (mRCC) treated with immune checkpoint inhibitors (ICI).
    Perimbeti, Stuthi
    Jiang, Changchuan
    Deng, Lei
    Roy, Arya
    Gopalakrishnan, Keerthy
    Chatta, Gurkamal S.
    George, Saby
    Gopalakrishnan, Dharmesh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [2] A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive nephrectomy
    Gross, Evan E.
    Li, Mingjia
    Yin, Ming
    Orcutt, Delaney
    Hussey, Duncan
    Trott, Elliot
    Holt, Sarah K.
    Dwyer, Erin R.
    Kramer, Joel
    Oliva, Kaylee
    Gore, John L.
    Schade, George R.
    Lin, Daniel W.
    Tykodi, Scott S.
    Hall, Evan T.
    Thompson, John A.
    Parikh, Anish
    Yang, Yuanquan
    Collier, Katharine A.
    Miah, Abdul
    Mori-Vogt, Sherry
    Hinkley, Megan
    Mortazavi, Amir
    Monk, Paul
    Folefac, Edmund
    Clinton, Steven K.
    Psutka, Sarah P.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (01) : 51.e25 - 51.e31
  • [3] Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN)
    Richey, S. L.
    Culp, S. H.
    Wood, C. G.
    Corn, P. G.
    Jonasch, E.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Outcome of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN)
    Richey, S. L.
    Culp, S. H.
    Jonasch, E.
    Corn, P. G.
    Pagliaro, L. C.
    Matin, S. F.
    Wood, C. G.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).
    Ghatalia, Pooja
    Handorf, Elizabeth A.
    Deng, Mengying
    Zibelman, Matthew R.
    Abbosh, Philip
    Anari, Fern
    Greenberg, Richard E.
    Viterbo, Rosalia
    Chen, David
    Smaldone, Marc C.
    Kutikov, Alexander
    Geynisman, Daniel M.
    Uzzo, Robert Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis
    Bakouny, Ziad
    Xie, Wanling
    Dudani, Shaan
    Wells, Connor
    Gan, Chun Loo
    Donskov, Frede
    Shapiro, Julia
    Davis, Ian D.
    Parnis, Francis
    Ravi, Praful
    Steinharter, John A.
    Agarwal, Neeraj
    Alva, Ajjai Shivaram
    Wood, Lori
    Kapoor, Anil
    Morales, Jose Manuel Ruiz
    Kollmannsberger, Christian K.
    Beuselinck, Benoit
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [7] Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN)
    Richey, S. L.
    Culp, S. H.
    Jonasch, E.
    Corn, P. G.
    Pagliaro, L. C.
    Tamboli, P.
    Patel, K.
    Matin, S. F.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [8] The comparison of cytoreductive nephrectomy (CN) with tyrosine kinase inhibitor therapy alone in patients with primary metastatic renal cell carcinoma (mRCC).
    Hatakeyama, Shingo
    Naito, Sei
    Numakura, Kazuyuki
    Kato, Renpei
    Koguchi, Tomoyuki
    Kojima, Takahiro
    Kawasaki, Yoshihide
    Kandori, Kandori
    Tsushima, Eiki
    Nishiyama, Hiroyuki
    Ito, Akihiro
    Kojima, Yoshiyuki
    Habuchi, Tomonori
    Obara, Wataru
    Tsuchiya, Norihiko
    Ohyama, Chikara
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [9] Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC)
    Vuong, Winston
    Chang, Mark
    Ruel, Nora
    Hsu, JoAnn
    Carmichael, Courtney
    Figlin, Robert A.
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Assessment of time from cytoreductive nephrectomy (CN) to initiation of targeted therapy (TT) in patients with metastatic renal cell carcinoma (mRCC).
    Vuong, Winston
    Chang, Mark
    Ruel, Nora
    Hsu, Joann
    Carmichael, Courtney
    Figlin, Robert A.
    Pal, Sumanta Kumar
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
12345